{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Venous+Thromboembolism",
    "query": {
      "condition": "Recurrent Venous Thromboembolism"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 17,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Venous+Thromboembolism&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T03:50:19.813Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04979780",
      "title": "Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Treatment of Venous Thromboembolism in Cancer Patients",
        "Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        },
        {
          "name": "Low molecular weight heparin (LMWH)",
          "type": "DRUG"
        },
        {
          "name": "Direct Oral Anticoagulants (DOAC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3708,
      "start_date": "2021-07-20",
      "completion_date": "2022-03-31",
      "has_results": false,
      "last_update_posted_date": "2024-10-31",
      "last_synced_at": "2026-07-24T03:50:19.813Z",
      "location_count": 1,
      "location_summary": "Multiple Locations, Connecticut",
      "locations": [
        {
          "city": "Multiple Locations",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04979780"
    },
    {
      "nct_id": "NCT05171049",
      "title": "A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Venous Thromboembolism",
        "Deep Venous Thrombosis",
        "Pulmonary Embolism"
      ],
      "interventions": [
        {
          "name": "Abelacimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Apixaban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Anthos Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1150,
      "start_date": "2022-05-05",
      "completion_date": "2026-02-04",
      "has_results": false,
      "last_update_posted_date": "2026-02-23",
      "last_synced_at": "2026-07-24T03:50:19.813Z",
      "location_count": 23,
      "location_summary": "Aurora, Colorado • West Haven, Connecticut • Washington D.C., District of Columbia + 19 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "West Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05171049"
    },
    {
      "nct_id": "NCT02064439",
      "title": "Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Embolism",
        "Thromboembolism",
        "Thrombosis",
        "Venous Thrombosis",
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "BAY 59-7939",
          "type": "DRUG"
        },
        {
          "name": "ASA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3365,
      "start_date": "2014-03-05",
      "completion_date": "2016-11-04",
      "has_results": true,
      "last_update_posted_date": "2017-12-19",
      "last_synced_at": "2026-07-24T03:50:19.813Z",
      "location_count": 24,
      "location_summary": "Beverly Hills, California • La Jolla, California • Ventura, California + 19 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Ventura",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02064439"
    },
    {
      "nct_id": "NCT00558259",
      "title": "Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "dabigatran etexilate 150 mg twice daily (BID)",
          "type": "DRUG"
        },
        {
          "name": "matching placebo twice daily (BID)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1353,
      "start_date": "2007-11",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2014-06-27",
      "last_synced_at": "2026-07-24T03:50:19.813Z",
      "location_count": 21,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Laguna Hills, California + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00558259"
    },
    {
      "nct_id": "NCT00986154",
      "title": "Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Venous Thromboembolism",
        "Deep Vein Thrombosis (DVT)",
        "Pulmonary Embolism (PE)",
        "Thromboembolism",
        "Venous Thrombosis"
      ],
      "interventions": [
        {
          "name": "edoxaban tosylate(DU-176b)",
          "type": "DRUG"
        },
        {
          "name": "low molecular weight heparin/unfractionated heparin",
          "type": "DRUG"
        },
        {
          "name": "warfarin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8292,
      "start_date": "2009-10",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2019-03-05",
      "last_synced_at": "2026-07-24T03:50:19.813Z",
      "location_count": 82,
      "location_summary": "Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 71 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00986154"
    },
    {
      "nct_id": "NCT04349189",
      "title": "Venous Thrombosis Biomarkers in Sickle Cell Disease and Sickle Cell Trait",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Sickle Cell Disease",
        "Venous Thrombosis",
        "Sickle Cell Trait",
        "Hypercoagulable State",
        "Venous Thromboembolism"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 119,
      "start_date": "2020-09-01",
      "completion_date": "2024-06-20",
      "has_results": false,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-07-24T03:50:19.813Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04349189"
    },
    {
      "nct_id": "NCT00439725",
      "title": "Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1197,
      "start_date": "2007-02",
      "completion_date": "2009-09",
      "has_results": true,
      "last_update_posted_date": "2014-11-04",
      "last_synced_at": "2026-07-24T03:50:19.813Z",
      "location_count": 25,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Redlands, California + 20 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Redlands",
          "state": "California"
        },
        {
          "city": "Bay Pines",
          "state": "Florida"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00439725"
    },
    {
      "nct_id": "NCT03214172",
      "title": "Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "2017-07-15",
      "completion_date": "2017-09-15",
      "has_results": false,
      "last_update_posted_date": "2018-09-06",
      "last_synced_at": "2026-07-24T03:50:19.813Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03214172"
    },
    {
      "nct_id": "NCT04168203",
      "title": "Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Deep Vein Thrombosis",
        "Pulmonary Embolism",
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Apixaban 2.5 MG",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 600,
      "start_date": "2021-03-01",
      "completion_date": "2025-04-08",
      "has_results": true,
      "last_update_posted_date": "2025-11-14",
      "last_synced_at": "2026-07-24T03:50:19.813Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04168203"
    },
    {
      "nct_id": "NCT00011180",
      "title": "Risk Factors for Venous Thromboembolism in the Community",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cardiovascular Diseases",
        "Thromboembolism"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 385,
      "start_date": "2001-04",
      "completion_date": "2009-05",
      "has_results": false,
      "last_update_posted_date": "2012-12-06",
      "last_synced_at": "2026-07-24T03:50:19.813Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00011180"
    }
  ]
}